公开(公告)号：US12187721B2

公开(公告)日：2025-01-07

申请号：US17285997

申请日：2019-10-17

Applicant: Array BioPharma Inc.

Inventor： James Francis Blake ,  Mark Laurence Boys ,  Mark Joseph Chicarelli ,  Adam Wade Cook ,  Mohamed S. A. Elsayed ,  Jay Bradford Fell ,  John Peter Fischer ,  Ronald Jay Hinklin ,  Oren Teague Mcnulty ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Christina Elizabeth Wong

IPC: C07D471/04 ,  C07D519/00

Abstract: Compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed

公开(公告)号：US11932633B2

公开(公告)日：2024-03-19

申请号：US17053273

申请日：2019-05-06

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  James F. Blake ,  Mark Joseph Chicarelli ,  Jay Bradford Fell ,  John P. Fischer ,  Erik James Hicken ,  Pavel Savechenkov ,  Tony Tang ,  Guy P. A. Vigers ,  Henry J. Zecca

IPC: C07D413/06 ,  A61P35/00 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P35/00 ,  C07D413/06

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20210380570A1

公开(公告)日：2021-12-09

申请号：US17053273

申请日：2019-05-06

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  James F. Blake ,  Mark Joseph Chicarelli ,  Jay Bradford Fell ,  John P. Fischer ,  Erik James Hicken ,  Pavel Savechenkov ,  Tony Tang ,  Guy P.A. Vigers ,  Henry J. Zecca

IPC: C07D413/14 ,  C07D413/06 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20180072723A1

公开(公告)日：2018-03-15

申请号：US15814279

申请日：2017-11-15

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Jay Bradford Fell ,  John P. Fischer ,  John J. Gaudino ,  Erik James Hicken ,  Ronald Jay Hinklin ,  Matthew Randolf Lee ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Henry J. Zecca

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20160368916A1

公开(公告)日：2016-12-22

申请号：US14988521

申请日：2016-01-05

Applicant: Array BioPharma Inc.

Inventor： Yvan Le Huerou ,  James F. Blake ,  Indrani W. Gunawardana ,  Peter J. Mohr ,  Eli M. Wallace ,  Bin Wang ,  Mark Joseph Chicarelli ,  Michael Lyon

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D401/06 ,  C07D519/00

Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US08883828B2

公开(公告)日：2014-11-11

申请号：US13669083

申请日：2012-11-05

Applicant: Array BioPharma Inc.

Inventor： Thomas Daniel Aicher ,  Steven Armen Boyd ,  Mark Joseph Chicarelli ,  Kevin Ronald Condroski ,  Ronald Jay Hinklin ,  Ajay Singh

IPC: A01N43/40 ,  C07D417/00 ,  C07D417/14 ,  C07D491/04 ,  C07D487/04 ,  C07D513/04 ,  C07D417/12 ,  C07D471/04 ,  C07D413/14 ,  C07D495/04

CPC classification number: C07D417/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

Abstract: Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

Abstract translation: 提供了可用于治疗和/或预防由缺乏水平的葡糖激酶活性（例如糖尿病）介导的疾病的化合物。 还提供了治疗或预防以葡萄糖激酶不足活性为特征的疾病和病症的方法，或者可以通过激活葡糖激酶治疗。

公开(公告)号：US20230357277A1

公开(公告)日：2023-11-09

申请号：US18027300

申请日：2021-09-21

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Matthew Arnold Marx ,  Shelley Allen ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Michael Christopher Hilton ,  Dean Russell Kahn ,  Macedonio Junior Mejia ,  Phong Nguyen ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Yu Savechenkov ,  Tony Pisal Tang

IPC: C07D519/00 ,  A61P35/00

CPC classification number: C07D519/00 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US10519126B2

公开(公告)日：2019-12-31

申请号：US15625297

申请日：2017-06-16

Applicant: Array BioPharma Inc. ,  Genentech, Inc.

Inventor： James F. Blake ,  Mark Joseph Chicarelli ,  Rustam Ferdinand Garrey ,  John Gaudino ,  Jonas Grina ,  David A. Moreno ,  Peter J. Mohr ,  Li Ren ,  Jacob Schwarz ,  Huifen Chen ,  Kirk Robarge ,  Aihe Zhou

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  A61K31/506 ,  A61K45/06 ,  C07F9/6558 ,  C07D403/04 ,  A61K31/513 ,  A61K31/53 ,  A61K31/444

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US09969727B2

公开(公告)日：2018-05-15

申请号：US14988521

申请日：2016-01-05

Applicant: Array BioPharma Inc.

Inventor： Yvan Le Huerou ,  James F. Blake ,  Indrani W. Gunawardana ,  Peter J. Mohr ,  Eli M. Wallace ,  Bin Wang ,  Mark Joseph Chicarelli ,  Michael Lyon

IPC: C07D471/04 ,  C07D519/00 ,  C07D401/06

CPC classification number: C07D471/04 ,  C07D401/06 ,  C07D519/00

Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US20160122316A1

公开(公告)日：2016-05-05

申请号：US14993985

申请日：2016-01-12

Applicant: ARRAY BIOPHARMA INC. ,  GENENTECH, INC.

Inventor： James F. Blake ,  Mark Joseph Chicarelli ,  Rustam Ferdinand Garrey ,  John Gaudino ,  Jonas Grina ,  David A. Moreno ,  Peter J. Mohr ,  Li Ren ,  Jacob Schwarz ,  Huifen Chen ,  Kirk Robarge ,  Aihe Zhou

IPC: C07D401/04 ,  C07D409/14 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D401/04 ,  A61K31/444 ,  A61K31/506 ,  A61K31/513 ,  A61K31/53 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07F9/65586

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.